Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Globe Newswire26-02-2024, 14:05
Wllex exchange: the new dark horse in the virtual currency 16-02-2023, 22:22